Bladder Cancer COE

The Association of Smoking Status with Recurrence in Patients with Predominantly High-Risk Recurrent NMIBC - Richard Matulewicz

Details
Richard Matulewicz joins Ashish Kamat presenting findings on the association of smoking status on recurrence of non-muscle invasive bladder cancer (NMIBC) in a contemporary cohort of patients with predominantly high-risk, recurrent NMIBC managed with photodynamic enhanced cystoscopy. A retrospective study was conducted in a multi-institutional registry. Smoking has a strong causal association with...

ctDNA Guiding Adjuvant Immunotherapy in Urothelial Carcinoma Journal Club – Christopher Wallis & Zachary Klaassen

Details
Christopher Wallis and Zachary Klaassen discuss a recently published paper, entitled, “ctDNA Guiding Adjuvant Immunotherapy in Urothelial Carcinoma.” They discuss the basics of circulating tumor DNA (ctDNA). He specifically discusses how we can use ctDNA to identify molecularly, or microscopic, residual disease. The study shows that ctDNA-positive patients with adjuvant atezolizumab, after surgery...

Choice of Urinary Diversion in Patients Undergoing Radical Cystectomy - Peter Black, Jens Bedke, and Hugh Mostafid

Details
Debate presenter, Peter Black joins Ashish Kamat along with discussants Jens Bedke, and Hugh Mostafid about urinary diversion in patients undergoing radical cystectomy. The 2021 European Association of Urology (EAU) annual meeting had a Controversies in Bladder Cancer Rapid-fire Debates session and here in this UroToday conversation, the group expands on their presentations with Ashish Kamat. Dr....

Bladder-Sparing Treatment Options for Muscle-Invasive Bladder Cancer – Andrea Necchi

Details
In this informative presentation from Andrea Necchi, MD, he presents information related to his goal of finding bladder-sparing treatment options for muscle-invasive bladder cancer (MIBC). Dr. Necchi begins his presentation with a discussion on recent immunotherapy studies for MIBC, the Balar, and IMMUNOPRESERVE studies. He presents evidence that both of these trials have displayed a promising amo...

The Clinical Impact and Molecular Drivers of ‘Secondary’ Muscle-Invasive Bladder Cancer - BCAN New Discoveries Young Investigator Award - Eugene J. Pietzak

Details
Eugene Pietzak, MD, Assistant Attending Surgeon of Urologic Oncology at Memorial Sloan Kettering Cancer Center in New York City received one of the five 2021 Bladder Cancer Advocacy Network (BCAN) New Discoveries Young Investigator Awards for his work in “Defining the Clinical Impact and Molecular Drivers of ‘Secondary’ Muscle-Invasive Bladder Cancer.” There are relatively well-established molecul...

Sexual Function in Women Undergoing Radical Cystectomy, BCAN New Discoveries Young Investigator Award for Patient-Centered Research - Svetlana Avulova

Details
Svetlana Avulova, MD, Urologic Oncology Fellow at Mayo Clinic received the 2021 BCAN New Discoveries Young Investigator Award for Patient-Centered Research. In this conversation with Ashish Kamat, MD she highlights her project titled “Sexual Function in Women Undergoing Radical Cystectomy”. There is a lack of research on women's quality of life, specifically, on the effect of radical cystectomy on...

Pembrolizumab in Combination With Gemcitabine and Concurrent Hypofractionated Radiation Therapy As Bladder Sparing Treatment for Muscle-Invasive Bladder Cancer - Arjun Balar

Details
In this conversation with Alicia Morgans, MD, MPH, Arjun Balar, MD highlights a multicenter study first designed in 2014 of gemcitabine hypofractionated radiation therapy and pembrolizumab all in combination as bladder-sparing therapy for patients with muscle-invasive bladder cancer that had a total of 54 patients. The goal of the study was to test the role of immunotherapy pembrolizumab added to...

A Study to Improve the Diagnosis of Bladder Cancer - BladderPath Study - Jim Catto & Gary Steinberg

Details
With the oncological safety of TURBT unknown, staging inaccuracies are commonplace, and correct treatment of muscle-invasive bladder cancer is potentially delayed. The BladderPath study is looking at using a multiparametric magnetic resonance imaging (mpMRI) scan to diagnose bladder cancer that has grown into the muscle. Drs. Jim Catto and Gary Steinberg join Dr. Ashish Kamat in a discussion about...

Novel Immune Checkpoint Axis To Understand BCG Resistance and Improve Treatment in Non-muscle Invasive Bladder Cancer - Amir Horowitz & John Sfakianos

Details
John Sfakianos and Amir Horowitz join Ashish Kamat discussing a novel immune checkpoint axis in non-muscle-invasive bladder cancer, specifically looking at the HLA-E and NKG2A axis in non-muscle invasive bladder cancer, as it relates to Bacillus Calmette-Guerin (BCG) and BCG resistance. Biographies: Amir Horowitz, Ph.D., is an Assistant Professor of Oncological Sciences and a member of the Precisi...

Conundrums in Bacillus Calmette Guerin (BCG) Unresponsive Nonmuscle Invasive Bladder Cancer Trials - Roger Li

Details
Joining Ashish Kamat from the Moffit Cancer Center in Tampa, Florida is Roger Li to dive into all things BCG unresponsive bladder cancer. Dr. Li shares what is known about BCG unresponsive disease, some of the conundrums that clinicians and the FDA are challenged by when evaluating and designing clinical trials in this area, and answers a series of questions from Dr. Kamat covering many topics in...